What is the recommended antiplatelet therapy regimen for a patient with acute ischemic stroke, including timing, dosing, and considerations for dual therapy and contraindications?

Antiplatelet Management in Acute Ischemic Stroke

For acute non-cardioembolic ischemic stroke, initiate aspirin 160 mg immediately after excluding intracranial hemorrhage on neuroimaging, then stratify by stroke severity: for minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), use dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel for 21 days; for moderate-to-severe stroke, continue aspirin monotherapy. 1, 2

Acute Phase Management (First 24-48 Hours)

Initial Antiplatelet Loading

All acute stroke patients not receiving thrombolysis require immediate aspirin loading:

• Loading dose: 160 mg aspirin (range 160-325 mg acceptable) 1, 2, 1
• Administer only after brain imaging excludes hemorrhage 1, 2
• Administer only after dysphagia screening is passed 2
• For dysphagic patients: rectal aspirin 325 mg daily OR enteral tube administration (aspirin 81 mg or clopidogrel 75 mg daily) 1

Critical timing consideration: If thrombolysis (alteplase) is administered, delay all antiplatelet therapy until 24-hour post-thrombolysis imaging excludes intracranial hemorrhage 2, 3. This is a firm contraindication to avoid compounding bleeding risk.

Dual Antiplatelet Therapy (DAPT) for Minor Stroke/High-Risk TIA

DAPT is indicated for specific high-risk populations only:

Eligibility Criteria

• Minor stroke: NIHSS ≤3 1, 2, 1
• High-risk TIA: ABCD2 score ≥4 1, 2, 1
• Non-cardioembolic etiology (cardioembolic strokes require anticoagulation, not DAPT) 1
• Symptom onset within 24 hours (ideally within 12 hours) 1, 2, 1

DAPT Regimen Options

Option 1: Aspirin + Clopidogrel (Most Evidence)

• Loading doses:
  • Aspirin 160-325 mg 1, 2, 1
  • Clopidogrel 300-600 mg (300 mg per CHANCE trial, 600 mg per POINT trial) 1, 2, 1
• Maintenance:
  • Aspirin 81 mg daily 1, 2, 1
  • Clopidogrel 75 mg daily 1, 2, 1
• Duration: 21 days (not 30 or 90 days—bleeding risk increases with longer duration) 1, 2, 1

Option 2: Aspirin + Ticagrelor (Alternative for NIHSS ≤5)

• Loading doses:
  • Aspirin 300-325 mg 1
  • Ticagrelor 180 mg 1
• Maintenance:
  • Aspirin 75-100 mg daily 1
  • Ticagrelor 90 mg twice daily 1
• Duration: 30 days 1

The 2023 World Stroke Organization guidelines 1 provide both options, though aspirin-clopidogrel has more robust evidence from CHANCE and POINT trials. The Canadian guidelines 2 specifically limit DAPT duration to 21-30 days based on POINT trial data showing that 90-day DAPT prevents 15 ischemic strokes per 1000 patients but causes 5 major hemorrhages per 1000 patients—an unacceptable risk-benefit ratio beyond the acute period.

Recent Evidence Supporting Extended DAPT Window

The 2023 INSPIRES trial 4 demonstrated that DAPT initiated within 72 hours (not just 24 hours) still reduces stroke recurrence (7.3% vs 9.2%, HR 0.79) in mild stroke/high-risk TIA of atherosclerotic origin, though with increased moderate-to-severe bleeding (0.9% vs 0.4%). This extends the treatment window but reinforces the bleeding risk trade-off. The 2025 meta-analysis 5 confirms DAPT benefit is greatest when initiated ≤24 hours to 7 days with loading doses and continued short-term (≤90 days).

Long-Term Antiplatelet Therapy (After DAPT Period)

After completing 21-30 days of DAPT, transition to single antiplatelet therapy indefinitely:

Monotherapy Options (All Equivalent for Long-Term Prevention)

• Aspirin 81-325 mg daily 1, 6
• Clopidogrel 75 mg daily 1, 6
• Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily 1, 6

The 2012 ACCP guidelines 6 suggest clopidogrel or aspirin/dipyridamole over aspirin alone for long-term prevention (Grade 2B), though all are acceptable. The 2023 World Stroke Organization guidelines 1 list all three as equivalent first-line options.

Critical counseling point: Patients must understand DAPT is temporary (21-30 days only), then they resume monotherapy indefinitely 2. Continuing DAPT beyond this period increases bleeding risk without additional benefit.

Special Populations and Contraindications

Moderate-to-Severe Stroke (NIHSS >3)

• Use aspirin monotherapy only (not DAPT) 2
• DAPT trials (CHANCE, POINT) excluded moderate-to-severe strokes
• The 2023 ARAMIS trial 7 showed DAPT was noninferior to alteplase in minor nondisabling stroke (NIHSS ≤5), but this does not extend to larger strokes

Intracranial Atherosclerotic Stenosis (50-99%)

• DAPT is appropriate medical therapy 1
• Angioplasty/stenting is not recommended 1
• Target systolic BP <140 mmHg and high-dose statin 1

Embolic Stroke of Undetermined Source (ESUS)

• Use antiplatelet therapy, not anticoagulation 1
• Anticoagulants showed no benefit over antiplatelets in ESUS trials 1

Extracranial Artery Dissection

• Either antiplatelet therapy OR anticoagulation for at least 3 months 1
• No clear superiority of one over the other 1

Cardioembolic Stroke (Atrial Fibrillation)

• Anticoagulation is required, not antiplatelet therapy 6
• Bridge with aspirin until therapeutic anticoagulation achieved 6
• Initiate anticoagulation within 1-2 weeks after stroke onset (earlier for small infarcts, later for large infarcts with hemorrhagic transformation risk) 6

Common Pitfalls and How to Avoid Them

Pitfall 1: Continuing DAPT Beyond 21-30 Days

Avoid: The POINT trial 2 showed bleeding risk outweighs benefit after 21-30 days. Explicitly counsel patients to stop dual therapy and resume monotherapy.

Pitfall 2: Using DAPT in Moderate-to-Severe Stroke

Avoid: DAPT is only for NIHSS ≤3 (or ≤5 for ticagrelor regimen). Larger strokes have higher bleeding risk without proven DAPT benefit.

Pitfall 3: Starting Antiplatelets Before Imaging

Avoid: Always exclude intracranial hemorrhage on CT/MRI before any antiplatelet therapy 1, 2, 1.

Pitfall 4: Starting Antiplatelets Within 24 Hours of Thrombolysis

Avoid: Wait for 24-hour post-thrombolysis scan to exclude hemorrhage 2, 3. This is non-negotiable.

Pitfall 5: Using DAPT in Cardioembolic Stroke

Avoid: Atrial fibrillation requires anticoagulation, not DAPT 6. Misclassifying stroke etiology leads to inappropriate therapy.

Pitfall 6: Delaying DAPT Initiation

Avoid: DAPT must start within 24 hours (ideally within 12 hours) for maximum benefit 1, 2, 1. The 2025 meta-analysis 5 confirms early initiation with loading doses is critical. Even the extended 72-hour window from INSPIRES 4 shows diminishing returns with delay.

Pitfall 7: Forgetting Dysphagia Screening

Avoid: Aspiration risk with oral medications is real. Screen swallowing before oral aspirin; use rectal or enteral routes if dysphagia present 1, 2, 1.

Bleeding Risk Considerations

GI protection may be considered in high-risk patients on DAPT 2. The Canadian guidelines 2 note extracranial bleeding was 0.9% with DAPT vs 0.4% with monotherapy in POINT (90-day study), though only 0.3% vs 0.3% in CHANCE (21-day study). The 2025 meta-analysis 5 confirms bleeding risk is slightly higher with aspirin-clopidogrel regimens and among women, but overall modest (pRR 1.29,95% CI 1.00-1.66).

For patients requiring urgent carotid endarterectomy or stenting: Consider aspirin monotherapy instead of DAPT to reduce perioperative bleeding risk—discuss with surgeon/interventionalist 2.

Summary Algorithm

1. Exclude hemorrhage on imaging → Screen for dysphagia
2. If thrombolysis given: Wait 24 hours, repeat imaging, then start antiplatelets
3. If no thrombolysis:
   • Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) + non-cardioembolic + <24 hours:
     • Load: Aspirin 160-325 mg + Clopidogrel 300-600 mg
     • Maintain: Aspirin 81 mg + Clopidogrel 75 mg daily × 21 days
     • Then: Switch to monotherapy (aspirin, clopidogrel, or aspirin/dipyridamole) indefinitely
   • All other strokes (NIHSS >3, cardioembolic, >24 hours):
     • Load: Aspirin 160 mg
     • Maintain: Aspirin 81-325 mg daily indefinitely (or alternative monotherapy)
     • If cardioembolic: Transition to anticoagulation within 1-2 weeks

This approach prioritizes mortality and morbidity reduction by preventing early recurrent stroke while minimizing bleeding complications, based on the highest-quality 2023 World Stroke Organization 1 and 2018 Canadian 2 guidelines, augmented by recent trial evidence 5, 4, 7.